Alumis, Inc. (ALMS)
20.03
+1.04
(+5.48%)
USD |
NASDAQ |
Jun 09, 16:00
20.03
0.00 (0.00%)
After-Hours: 20:00
Alumis SG&A Expense (Quarterly) : 18.61M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Nektar Therapeutics | 13.44M |
| Bristol Myers Squibb Co. | 1.617B |
| Amylyx Pharmaceuticals, Inc. | 16.17M |
| Aardvark Therapeutics, Inc. | 5.897M |
| Johnson & Johnson | 6.034B |